Table 2.

Hazard ratios (HR) and 95% confidence intervals (CI) of primary, secondary, and other outcomes by randomized assignment to n-3 fatty acids (n-3 FAs)^a

Endpoint	n-3 FAs (N =12,933)	Placebo (N =12,938)	HR	95% CI
	# of participants w/event
Cardiovascular disease (CVD), primary and secondary outcomes
Major CVD eventb,c	386	419	0.92	0.80–1.06
Expanded CVD eventd	527	567	0.93	0.82–1.04
Total myocardial infarction (MI)	145	200	0.72	0.59–0.90
Total stroke	148	142	1.04	0.83–1.31
Cardiovascular mortality	142	148	0.96	0.76–1.21
Other vascular outcomese
Percutaneous coronary intervention (PCI)	162	208	0.78	0.63–0.95
Coronary artery bypass graft (CABG)	85	86	0.99	0.73–1.33
Fatal MI	13	26	0.50	0.26–0.97
Coronary heart disease (CHD) mortality	37	49	0.76	0.49–1.16
Total CHDf	308	370	0.83	0.71–0.97
Ischemic stroke	111	116	0.96	0.74–1.24
Hemorrhagic stroke	25	19	1.32	0.72–2.39
Fatal stroke	22	20	1.10	0.60–2.01
Total invasive cancerb	820	797	1.03	0.93–1.13
Cancer mortality	168	173	0.97	0.79–1.20
All-cause mortality	493	485	1.02	0.90–1.15
Excluding the first two years of follow-up:
Cardiovascular outcomes
Major CVD event	269	301	0.89	0.76–1.05
Total myocardial infarction	94	131	0.72	0.55–0.93
Total stroke	103	112	0.92	0.70–1.20
Total invasive cancer	536	476	1.13	1.00–1.28
Cancer mortality	126	135	0.93	0.73–1.19
All-cause mortality	371	381	0.97	0.84–1.12

^aAnalyses were from Cox regression models that were controlled for age, sex, and randomization group in the vitamin D portion of the trial. Analyses were not adjusted for multiple comparisons.

^bPrimary outcomes

^cA composite of MI, stroke, and cardiovascular mortality

^dA composite of MI, stroke, cardiovascular mortality, and coronary revascularization (CABG, PCI)

^eNot prespecified as primary or secondary outcomes.

^fA composite of MI, coronary revascularization (CABG, PCI), and CHD death